SCHEMBL7053657

SCHEMBL7053657

COc1cc2sc(-c3ccccc3)nc2c(C)c1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.45
KDM4E B2RXH2 4/20 0.45
NFKB1 P19838 3/20 0.45
NFKB2 Q00653 3/20 0.45
RELA Q04206 3/20 0.45
LMNA P02545 2/20 0.45
NPC1 O15118 4/20 0.44
RAB9A P51151 4/20 0.44
HPGD P15428 3/20 0.44
PKM P14618 2/20 0.44
RARA P10276 1/20 0.43
RARB P10826 1/20 0.43
RARG P13631 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
MAPT P10636 3/20 0.41
TRPM8 Q7Z2W7 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
ADORA1 P30542 1/20 0.41
ALDH1A1 P00352 3/20 0.41
MEN1 O00255 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5415103 0.90 SULT1A1 (0.46) SMN1; SMN2KDM4ENPC1RAB9APKM
SCHEMBL5068352 0.81 SMN1; SMN2 (0.55) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL9435301 0.74 KDM4E (0.57) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL11239816 0.73 SMN1; SMN2 (0.50) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL2137298 0.73 SMN1; SMN2 (0.51) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL5946259 0.72 NQO2 (0.49) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL5946180 0.72 TTR (0.42) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL143850 0.71 ALDH1A1 (0.59) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL7053654 0.71 SMN1; SMN2 (0.56) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL9620871 0.70 DYRK1A (0.53) SMN1; SMN2KDM4ENFKB1NFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030162766-A1 Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists PFIZER INC. 2003-08-28 US disclosed
US-6369074-B1 Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists PFIZER INC. 2002-04-09 US disclosed
US-20010023248-A1 Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists HOWARD HARRY R (US) 2001-09-20 US disclosed
US-5854262-A Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists PFIZER INC. (US) 1998-12-29 US disclosed
EP-0806423-A1 Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists PFIZER INC. (US) 1997-11-12 EP disclosed
WO-1994013663-A1 AMINOMETHYLENE SUBSTITUTED NON-AROMATIC HETEROCYCLES AND USE AS SUBSTANCE P ANTAGONISTS PFIZER INC. (US) 1994-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010023248-A1 Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists NPY1R, OPRK1, OPRL1 SMN1; SMN2 1543/4885KDM4E 1271/4885NFKB1 1042/4885
US-20030162766-A1 Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists NPY1R, OPRK1, TACR1 SMN1; SMN2 1485/4885KDM4E 1245/4885NFKB1 1258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.